Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.

Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, Hommes DW, Tanke HJ.

Anal Bioanal Chem. 2013 Sep;405(23):7367-75. doi: 10.1007/s00216-013-7154-0. Epub 2013 Jul 9.

PMID:
23836086
2.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

4.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Am J Gastroenterol. 2014 Jul;109(7):1055-64. doi: 10.1038/ajg.2014.106. Epub 2014 May 6.

PMID:
24796769
5.

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.

J Crohns Colitis. 2015 Mar;9(3):238-45. doi: 10.1093/ecco-jcc/jjv004. Epub 2015 Jan 9.

PMID:
25576753
6.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
7.

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K.

Ther Drug Monit. 2013 Aug;35(4):530-8. doi: 10.1097/FTD.0b013e31828d23c3.

PMID:
23765033
8.

Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.

Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, Gils A.

Ther Drug Monit. 2015 Aug;37(4):479-85. doi: 10.1097/FTD.0000000000000162.

PMID:
25525757
9.

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.

Warman A, Straathof JW, Derijks LJ.

Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242-8. doi: 10.1097/MEG.0000000000000279.

PMID:
25569569
10.

Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.

Hernández-Breijo B, Chaparro M, Cano-Martínez D, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Gisbert JP, Guijarro LG; PREDICROHN study group from GETECCU.

Biochem Pharmacol. 2016 Dec 15;122:33-41. doi: 10.1016/j.bcp.2016.09.019. Epub 2016 Sep 21.

PMID:
27664854
11.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Nanda KS, Cheifetz AS, Moss AC.

Am J Gastroenterol. 2013 Jan;108(1):40-7; quiz 48. doi: 10.1038/ajg.2012.363. Epub 2012 Nov 13. Review.

12.

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.

Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S.

Inflamm Bowel Dis. 2012 Sep;18(9):1628-33. doi: 10.1002/ibd.21919. Epub 2011 Oct 29.

PMID:
22038899
13.

Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.

Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky MC.

Inflamm Bowel Dis. 2014 Oct;20(10):1708-13. doi: 10.1097/MIB.0000000000000137.

PMID:
25153505
14.

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.

Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.

J Gastroenterol. 2014 Apr;49(4):674-82. doi: 10.1007/s00535-013-0829-7. Epub 2013 May 11.

PMID:
23666424
15.

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.

PMID:
23878167
16.

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.

Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S.

J Immunol Methods. 2012 Aug 31;382(1-2):177-88. doi: 10.1016/j.jim.2012.06.002. Epub 2012 Jun 9.

17.

Significance of low level infliximab in the absence of anti-infliximab antibodies.

Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S.

World J Gastroenterol. 2015 Feb 14;21(6):1907-14. doi: 10.3748/wjg.v21.i6.1907.

18.

Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.

Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.

PMID:
23419382
19.

Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.

Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y.

Inflamm Bowel Dis. 2010 Nov;16(11):1898-904. doi: 10.1002/ibd.21259.

PMID:
20310016
20.

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.

Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, Nielsen OH.

Medicine (Baltimore). 2016 Apr;95(16):e3417. doi: 10.1097/MD.0000000000003417.

Supplemental Content

Support Center